Search

everythinglearnresearchcommunity

for

Search:↓

RU58841 powder from a lab supplier was tested at a free drug testing service. The discussion includes using Minoxidil and finasteride for hair loss treatment.

PP405 is likely fake, and JXL069 is an unrefined prototype with unknown side effects. It's advised to wait for the official PP405 release.

RU58841 for hair loss, discussing sources, application methods, and carriers like PG + ethanol or liquid minoxidil. Users share experiences with premixed solutions and powder forms, noting price differences and storage importance.

The conversation discusses the delay in the release of GT20029 for hair loss treatment and skepticism about its effectiveness. Participants mention other treatments like verteporfin and advancements in transplant procedures as more realistic options.

The conversation discusses potential advancements in two hair loss drugs, KX-826 and GT20029, and the interest in whether transitioning from oral finasteride to these drugs would maintain hair growth. One reply expresses skepticism about the compounds' representation.

PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.

A user is considering buying RU58841 powder from Aliexpress to mix with Minoxidil for hair loss treatment. Another user warns about the safety concerns of RU58841, especially from unreliable sources, and suggests trying finasteride, oral Minoxidil, and dutasteride first.

A 37-year-old man is seeking advice for hair loss treatment, considering options like finasteride and topical or oral minoxidil. A user suggests consulting a doctor and monitoring blood pressure if using oral minoxidil.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

The conversation discusses interest in participating in PP405 trials for hair loss treatment, with users expressing uncertainty about eligibility due to location. Participants are eager for updates and willing to pay for shipping if trials are limited to America.

A user ordered H&W's 1.25% Topical Finasteride and is curious about others' experiences and side effects. Another user asked about availability in the US.

Hair loss discussion includes treatments like Minoxidil, Finasteride, and RU58841. Users seek Alfatradiol sources and share personal experiences.

The conversation discusses a new liposomal topical finasteride from Hasson and Wong, available in Canada and Italy, soon in the US, costing $40/month. It claims to reduce scalp DHT by 50% without affecting serum DHT, potentially benefiting those who can't tolerate oral finasteride or RU58841.

RU58841 from Vantanex is discussed for hair loss treatment. Users share experiences and question its legitimacy.

The user is considering a hair transplant at 25 after experiencing hair loss despite using finasteride, minoxidil, and recently starting dutasteride. They are advised to continue DHT blockers post-transplant to prevent further hair loss and are considered an ideal candidate for a transplant.

A 29-year-old is using liposomal topical finasteride/minoxidil and low-level light therapy (LLLT) to improve hair growth, showing significant progress in crown recovery. The user prefers liposomal topicals to avoid side effects from oral finasteride and uses the iRestore Essential device for LLLT.

A user started using RU58841 for hair loss and experienced anxiety and physical discomfort. Other users suggested avoiding the treatment due to similar side effects and recommended alternative treatments like pyri.

Kintor Pharma completed enrolling subjects for a Phase III trial of KX-826 for male hair loss treatment. The trial includes a 24-week treatment period and a 4-week safety follow-up, with results expected in about 6-7 months.

A 26-year-old male considering a hair transplant is using topical finasteride and minoxidil, planning to start feminizing hormone replacement therapy (HRT) with estrogen and spironolactone. Many suggest waiting to see the effects of HRT, which may significantly regrow hair, before deciding on a transplant, and recommend adding microneedling and possibly switching to oral treatments for better results.

Hair loss may be linked to the TRPS1 gene and protein, not just DHT. Amplifica's AMP-303 targets mesenchymal stem cells and shows promise in treating hair loss, unlike Pelage's PP405.

A 28-year-old man shared his experience with a 2990 graft FUE hair transplant at HDC Clinic in Cyprus, praising the professionalism and care received. He has been using topical Minoxidil, Biotin, Dermarolling, and recently started Finasteride and oral Minoxidil.

Fluridil's effectiveness and safety in treating hair loss are discussed, with higher concentrations showing potential success. Comparisons are made to other treatments like RU58841, Pyri, CB-03-01, and topical spironalactone.

Using PP405 and Clascoterone after a hair transplant may not cause issues if the transplant didn't achieve native density, but could lead to competition for blood supply if it did. Some users suggest waiting for these drugs to be available, as they might not significantly impact blood supply or regrowth.

A 23-year-old is struggling with hair loss despite using minoxidil, finasteride, and dutasteride, and is considering increasing the dutasteride dosage. They are advised to try ketoconazole or salicylic acid shampoo for an oily scalp and consider microneedling.

People are discussing ordering pyrilutamide for hair loss treatment in the US. The treatment is from Kintor's subsidiary company and is available on Amazon.

A 42-year-old is using dutasteride, oral and topical minoxidil, ketoconazole, and a dermaroller for hair loss, with noticeable progress after six months. They are questioning if further gains are possible and considering stopping the dermaroller, as advised that future improvements may only involve hair thickening.

The conversation discusses using GHK-Cu for hair loss, with one user suggesting subcutaneous administration for better control. The effectiveness of topical application is questioned due to a lack of reliable reviews.

GHK-Cu injections led to unexpected temple hair growth for someone who had been using minoxidil and finasteride for over a decade. The user plans to continue using GHK-Cu and experiment with a DIY AHK-Cu serum.

AHK-Cu peptide is considered better than GHK-Cu for hair growth. The user is seeking recommendations for trusted AHK-Cu peptide brands with third-party testing.

The conversation is about a user expressing concerns over the safety of a new drug called Pyrilutamide (also known as KX-826) for hair loss. The user will only trust the drug if it's permitted by EU regulations and sold by a reputable company.